Current perspectives for treatment of breast cancer

Breast Cancer

Volumn 7, Issue 4, 2000, Pages 380-388

  Bunnell, Craig ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant; Breast cancer; Herceptin; Metastatic; Taxanes

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PACLITAXEL; TRASTUZUMAB;

BREAST TUMOR; FEMALE; HUMAN; REVIEW;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; PACLITAXEL;

EID: 0034565501     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02966408     Document Type: Article

References (31)

1. Nabholtz JM, Gelman K, Bontenbal M, et al'. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J. Clin Oncol 14:1858-1867, 1996. (Pubitemid 26185461)
2. Winer E, Berry D, Duggan D, et al: Failure of higher dose paclitaxel to improve outcome in patients with metastatic breast cancer-results from CALGB 9342. ProcAm Soc Clin Oncol 17:101, 1998 (abstract 388).
3. Peretz T, Sulkes A, Chollet P, et al: A multicenter, randomized study of two schedules of paclitaxel in patients with advanced breast cancer. Eur J Cancer 31A(suppl 5): S75, 1995 (abstract 345).
4. Mamounas E, Brown A, Smith R, et al: Effect of Taxol duration of infusion in advanced breast cancer (ABC): Results from NSABP B-26 trial comparing 3-2 24-hour infusion of high-dose Taxol. Proc Am Soc Clin Oncol 17:101, 1998 (abstract 389).
5. Holmes FA, Valero V, Walters R, et al: Phase III trial of paclitaxel administered over a 3-hour or 96-hour for metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 15:106, 1996 (abstract 91).
6. Holmes FA, Valero V, Buzdar AU, et al: Final results: Randomized phase III trial of paclitaxel by 3-hour versus 96-hour infusion in patients with metastatic breast cancer (MBC). The long and short of it. Proc Am Soc Clin Oncol 17:110, 1998 (abstract 426).
7. Seidman AD, Hochhauser D, Gollub M, et al: 96-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinefic and pharmacodynamic study in metastatic breast cancer. J. Clin Oncol 14:1877-1884, 1996.
8. Nabholz JM, Senn HJ, Bezwoda WR, et al: Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J. Clin Oncol 17:1413-1424, 1999. (Pubitemid 29220847)
9. Chan S, Ffiedrichs K, Noel D, et al: A phase III study of Taxotere versus doxorubicin in patients with metastatic breast cancer (MBC) who have failed an alkylating-containing regimen. Breast Cancer Res Treatment 46:23, 1997 (abstract 1).
10. Fumoleau P, Chevallier B, Kerbrat P, et al : A multicenter phase II study of the efficacy and safety of docetaxel and first-line treatment of advanced breast cancer: Report of the Clinical Screening Group of the EORTC. Ann Oncol 7:165-171, 1996. (Pubitemid 26094881)
11. O'Brien M, Leonard R, Barrett-Lee PJ, et al: Docetaxel in the community setting: An analysis of 377 breast cancer patients treated with docetaxel (Taxotere) in the UK. Ann Oncol 10:205-210, 1999. (Pubitemid 29113181)
12. Trudeau ME, Eisenhauer EA, Higgins BP, et al: Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin Oncol 14:422-428, 1996.
13. Archer CD, Lowdell C, Sinnett HD, et al: Docetaxel: response in patients who have received at least two prior chemotherapy regimens for metastatic breast cancer. Eur J. Cancer 34:816-819, 1998. (Pubitemid 28248490)
14. Ravdin PM, Burfis HA, Cook G, et al: Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J. Clin Oncol 13:2879-2885, 1995.
15. Hudis CA, Seidman AD, Crown JPA, et al: Phase II and pharmacological study of docetaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol14:58-65, 1996.
16. Seidman AD, Hudis CA, Albanel J, et al: Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 16:3353-3361, 1998. (Pubitemid 28481632)
17. Loesch D, Robert N, Dakhil S, et al: Phase II trial of weekly Taxol, 5-fluorouracil and leucovorin regimen in patients with metastatic breast cancer: An update. Proc Am Soc Clin Oncol 18:117, 1999 (abstract 445).
18. Perez EA, Irwin DH, Patel IL et al: A large phase II trial of paclitaxel administered as a weekly 1-hour infusion in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 18:126, 1999 (abstract 480).
19. Fornier M, Seidman AD, Esteva FJ, et al: Weekly Herceptin plus 1-hour Taxol: phase II study in HER2-overexpressing and non-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 18:126, 1999 (abstract 482).
20. Breier S, Lebedinsky C, Pelayes L, et al: Phase I/II weekly paclitaxel 80 mg/m 2 in pre-treated patients with breast or ovarian cancer. Proc Am Soc Clin Oncol 16:163, 1997 (abstract 568).
21. Burstein HJ, Younger J, Bunnell CA, et al: Weekly docetaxel (Taxotere) for metastatic breast cancer: A phase II trial. Proc Am Soc Clin Oncol 18:127, 1999 (abstract 484).
22. Loffler TM, Freund W, Droge C, et al: Activity of weekly Taxotere in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 17:113, 1998 (abstract 435).
23. Climent MA, Ruiz A, Llombart-Cussac A, et al: Weekly docetaxel in patients with advanced malignancies. Toxicity profile and activity results. Proe Am Soc Clin Oncol 18:119, 1999 (abstract 453).
24. Piccart MJ, Klijn J, Paridaens R, et al: Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for Research and Treatment of Investigational Drug Branch for Breast Cancer. J Clin Oncol15:3149-3155, 1997. (Pubitemid 27377507)
25. Robert N, Loesch D, Dakhil S, et al Phase II trial of weekly Taxotere, 5-fluorouracil, and leucovorin in patients with advanced breast cancer. Proc Am Soc Clin Oncol 18:119, 1999 (abstract 451).
26. Cobleigh MA, Vogel CL, Tripathy D, et al Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol17:2639-2648, 1999. (Pubitemid 29415219)
27. Slamon D, Leyland-Jones B, Shak S, et al: The addition of Herceptin (humanized anti-HER2 antibody) to first-line chemotherapy for HER2-overexpressing metastatic breast cancer (HER2+ MBC) markedly increases anti-cancer activity: A randomized, multinational controlled phase II trial. Proc Am Soc Clin Oncol 17:98, 1998 (abstract 377).
28. Norton L, Slamon D, Leyland-Jones B, et al Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Hercepfin in HER2-overexpressing (HER2+) metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 18: 127, 1999 (abstract 483).
29. Fornier M, Seidman AD, Esteva FJ, et al Weekly Hercepfin and 1 hour taxol: Phase II study in HER,?, overexpressing and non-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 18:126a, 1999 (abstract 482).
30. Henderson IC, Berry D, Demetri G, et al: Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC). Proc Am Soc Clin Oncol 17:101a, 1998 (abstract 390).
31. Taxob (paclitaxel) injection official prescribing information, Bristol-Myers Squibb Company, Princeton, NJ, 1999.